Timing note: Lilly is scheduled to report today, Wednesday, August 5, 2026, before the U.S. market opens—not tomorrow. The earnings call begins at 10:00 a.m. ET. (investor.lilly.com)
Lilly enters Q2 with exceptional operating momentum but an equally demanding valuation and expectations bar. Public consensus data point to roughly:
| Metric | Q2 2026 expectation | Q2 2025 actual | Implied growth |
|---|---|---|---|
| Revenue | ~$20.5B | $15.56B | ~32% |
| Adjusted EPS | ~$8.8 | $6.31 | ~40% |
Consensus varies across public aggregators, particularly for EPS, but approximately $20.5 billion of revenue and high-$8 adjusted EPS appear to be the most consistent current benchmarks. (investing.com)
The stock closed August 4 near $1,116, roughly 31% above its pre-Q1 level but about 11% below its recent 52-week high. The pullback offers some cushion, although investors are still pricing in sustained dominance of the obesity market and successful commercialization of Lilly’s next-generation portfolio. (marketbeat.com)
Mounjaro and Zepbound remain the central earnings driver. In Q1:
Q1 revenue benefited from a favorable one-time adjustment to rebate and discount estimates for both products. That makes the sequential comparison less clean: underlying demand can remain strong even if reported Q2 growth looks less dramatic. Lilly also expects lower realized prices to remain a low-to-mid-teens headwind for 2026. (investor.lilly.com)
Investors should focus on four components:
U.S. Zepbound volume.
The key test is whether prescription and patient growth continues to offset lower cash-pay prices and broader rebate pressure.
International Mounjaro.
This is arguably the most important source of upside. Q1 international revenue rose sharply as Lilly expanded access and gained share, particularly in China and other large markets. Morgan Stanley reportedly modeled Q2 international Mounjaro sales of $4.8B versus consensus around $4.5B. (finance.yahoo.com)
Net price versus volume.
Lilly’s thesis is that lower prices expand the addressable market enough to produce greater revenue and profit dollars. The report needs to show that this elasticity is still working.
Channel and inventory effects.
Tirzepatide now represents enough of Lilly’s business that wholesaler inventory, rebate true-ups or changes in channel mix can materially move quarterly revenue. Investors should separate those items from underlying prescription demand.
A strong result would show sequential growth in combined Mounjaro and Zepbound sales even after adjusting for Q1’s favorable rebate item.
Foundayo, Lilly’s once-daily oral GLP-1, became broadly available in the U.S. on April 9. It can be taken without food or water restrictions and was launched with self-pay pricing starting at $149 per month for the lowest dose. (investor.lilly.com)
Q2 captures only the first several weeks of commercialization. Moreover:
Accordingly, absolute Q2 revenue is unlikely to be the best measure of launch success. More useful indicators include:
The Medicare GLP-1 Bridge program is an important second-half catalyst. Eligible Medicare Part D patients can access Foundayo or Zepbound for $50 per month beginning July 1, with the program scheduled to run through December 2027. Lilly estimates approximately 20 million Medicare patients may meet the clinical criteria, although prior authorization and implementation capacity could make uptake gradual. (investor.lilly.com)
The earnings call should therefore provide the first meaningful indication of whether Foundayo is tracking toward a Q3/Q4 inflection.
After Q1, Lilly raised 2026 guidance to:
Q1 produced $19.8B of revenue. If Q2 lands near $20.5B, Lilly would enter the second half with approximately $40.3B, requiring:
The low end appears relatively conservative given Medicare access, Foundayo promotion and continuing international expansion. The high end requires a more meaningful second-half acceleration, but it remains attainable. JPMorgan entered the report expecting $20.7B of Q2 revenue and another potential guidance increase. (itiger.com)
A guidance raise would be positive, but investors should ask what drives it:
Investors should also be careful with EPS comparisons. Lilly’s non-GAAP EPS can include acquired in-process R&D charges, while its guidance excludes acquired IPR&D incurred after March 31. Recent acquisition activity could therefore create noise between reported EPS and the underlying operating run rate.
Q1 adjusted gross margin was 82.6%, down approximately 90 basis points year over year because of lower realized prices. At the same time, operating leverage lifted Lilly’s performance margin to 50%.
For Q2, investors should watch:
Lilly is generating substantially more cash, but it is also funding manufacturing capacity and a broad pipeline while pursuing multiple acquisitions. Buybacks become less obviously attractive when the stock trades at a premium valuation, so management’s capital-allocation commentary deserves attention.
Retatrutide remains the most important pipeline asset. Recent Phase 3 data included:
Lilly now plans to submit retatrutide for U.S. approval in Q1 2027, rather than during the second half of 2026 as discussed at its June investor event. Investors should listen for whether that timing reflects only completion of the manufacturing and regulatory package or any broader execution risk. (investor.lilly.com)
Other relevant pipeline questions include:
This report is less about whether Lilly can produce another year-over-year growth quarter—the business is almost certain to do so—and more about whether its growth algorithm remains strong enough to support premium expectations.
The three decisive variables are:
A modest headline beat may not be sufficient if tirzepatide trends or Foundayo leading indicators weaken. Conversely, strong underlying volume, an improving second-half launch trajectory and a guidance increase would reinforce the view that Lilly is evolving from a two-product obesity story into a broader, durable cardiometabolic platform.